


PROTAC BRD4 Degradar-2

Cat. No.:	HY-133136
CAS No.:	2185795-53-1
Molecular Formula:	C ₄₀ H ₃₉ N ₉ O ₇
Molecular Weight:	757.79
Target:	PROTACs; Epigenetic Reader Domain
Pathway:	PROTAC; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PROTAC BRD4 Degradar-2 is a PROTAC connected by ligands for Cereblon and BRD4 with an IC ₅₀ of 14.2 nM against BRD4 BD1 ^[1] .									
IC₅₀ & Target	BRD4 BD1 14.2 nM (IC ₅₀)	Cereblon								
In Vitro	<p>PROTAC BRD4 Degradar-2 (Compound 17) inhibits the growth of THP-1 cell line with an IC₅₀ of 1.83±0.016 μM^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human monocyte lymphoma cell line THP-1</td> </tr> <tr> <td>Concentration:</td> <td>72 hours</td> </tr> <tr> <td>Incubation Time:</td> <td>0.81-3.26 μM</td> </tr> <tr> <td>Result:</td> <td>Showd high anti-proliferative potency.</td> </tr> </table>		Cell Line:	Human monocyte lymphoma cell line THP-1	Concentration:	72 hours	Incubation Time:	0.81-3.26 μM	Result:	Showd high anti-proliferative potency.
Cell Line:	Human monocyte lymphoma cell line THP-1									
Concentration:	72 hours									
Incubation Time:	0.81-3.26 μM									
Result:	Showd high anti-proliferative potency.									

REFERENCES

[1]. Zhang F, et al. Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. *Bioorg Med Chem.* 2020 Jan 1;28(1):115228.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA